- Home
- SEDG vs IMCR Comparison
SEDG vs IMCR Comparison
Compare SEDG & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEDG | IMCR |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2015 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SEDG | IMCR |
|---|---|---|
| Price | $33.59 | $33.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 19 | 11 |
| Target Price | $28.20 | ★ $64.70 |
| AVG Volume (30 Days) | ★ 3.3M | 379.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.26 | 30.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,184,444,000.00 | $249,428,000.00 |
| Revenue This Year | $16.93 | $14.39 |
| Revenue Next Year | $12.92 | $8.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 31.39 | ★ 43.05 |
| 52 Week Low | $11.00 | $23.15 |
| 52 Week High | $48.60 | $40.71 |
Technical Indicators
Market Signals| Indicator | SEDG | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 50.92 |
| Support Level | $30.04 | $31.21 |
| Resistance Level | $33.97 | $34.86 |
| Average True Range (ATR) | 3.54 | 1.72 |
| MACD | -0.61 | 0.10 |
| Stochastic Oscillator | 9.74 | 57.18 |
Price Performance
Historical ComparisonAbout SEDG SolarEdge Technologies Inc.
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.